Is iBio, Inc. Common Stock (IBIO) overvalued? · rev $100.0K
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
This page asks whether iBio, Inc. Common Stock (IBIO) looks expensive on cached numbers — not a short thesis.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
IBIO currently screens at market cap $13.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IBIO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IBIO stock page for the full model, not this heading.
Not investment advice.